Literature DB >> 3474061

Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.

G Capranico, A Riva, S Tinelli, T Dasdia, F Zunino.   

Abstract

DNA single-strand and double-strand breaks produced by doxorubicin and two anthracycline derivatives (4-demethoxy-daunorubicin and 4'-deoxy-4'-iododoxorubicin) were measured in doxorubicin-sensitive and -resistant P388 leukemia cell lines, using filter elution methods, and compared with cellular drug accumulation to account for major differences in their cytotoxic activities and cross-resistance. The increased cytotoxic potency of the two derivatives reflects at least in part the enhanced drug accumulation by cells that results from their increased lipophilicity. However, the level of protein-linked DNA breaks was not directly related to cellular accumulation of drug analogues. It is possible that enhanced cytotoxicity may also be the consequence of the greatly enhanced ability of analogues to cause DNA strand breaks. The resistant line showed only a modest degree of resistance to both anthracycline derivatives compared with the high degree of resistance to doxorubicin. Although for all the anthracyclines tested drug accumulation was reduced in the resistant line, this did not correlate with the degree of resistance. A differential sensitivity of resistant and parental cell lines to DNA cleavage activity was consistently found for all three drugs tested. However, in contrast to a lack of effect of doxorubicin, the derivatives caused appreciable DNA strand breakage in resistant cells. The enhanced ability of these analogues to break DNA in resistant cells is consistent with the slight cross-resistance with doxorubicin. DNA double-strand breaks produced in isolated nuclei from these cells paralleled the pattern found in whole cells, thus indicating that a nuclear alteration, presumably involving DNA topoisomerases, is associated with anthracycline resistance. Our findings strongly support the hypothesis that anthracycline resistance in these cell variants may be mediated by multiple mechanisms, involving alterations of plasma membrane and changes of nuclear enzymatic activities responsible for DNA strand breaks.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3474061

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

Review 1.  Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  L M Hollingshead; D Faulds
Journal:  Drugs       Date:  1991-10       Impact factor: 9.546

2.  Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.

Authors:  R Supino; M Mariani; E Prosperi; G Parmiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.

Authors:  D W Roberts; P D Foglesong; E Parganas; L Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Drugging topoisomerases: lessons and challenges.

Authors:  Yves Pommier
Journal:  ACS Chem Biol       Date:  2013-01-04       Impact factor: 5.100

5.  Cytotoxicity of adriamycin, idarubicin, and vincristine in acute myeloid leukemia: chemosensitization by verapamil in relation to P-glycoprotein expression.

Authors:  M R Müller; K Lennartz; C Boogen; M R Nowrousian; M F Rajewsky; S Seeber
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

6.  Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.

Authors:  R Supino; M Mariani; G Capranico; A Colombo; G Parmiani
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

7.  P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines.

Authors:  G Capranico; P De Isabella; C Castelli; R Supino; G Parmiani; F Zunino
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

8.  Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells.

Authors:  Moshe Giladi; Mijal Munster; Rosa S Schneiderman; Tali Voloshin; Yaara Porat; Roni Blat; Katarzyna Zielinska-Chomej; Petra Hååg; Ze'ev Bomzon; Eilon D Kirson; Uri Weinberg; Kristina Viktorsson; Rolf Lewensohn; Yoram Palti
Journal:  Radiat Oncol       Date:  2017-12-29       Impact factor: 3.481

9.  Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations.

Authors:  Kate E Coldwell; Suzanne M Cutts; Ted J Ognibene; Paul T Henderson; Don R Phillips
Journal:  Nucleic Acids Res       Date:  2008-07-16       Impact factor: 16.971

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.